Arthur Hung
OHSU Knight Cancer Institute
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Arthur Hung as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 03:14 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06528210 · Pembrolizumab With Androgen Deprivation Therapy and Radiotherapy for the Treatment of Patients With High Risk Localized Prostate CancerOHSU Knight Cancer Institute · withdrawn · High Risk Prostate Carcinoma, Localized Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8 · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 03:14 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 03:14 UTC. The ranking covers the 200 most relevant of 51 PubMed records, and a shared surname and initials can bring in a namesake. All 51 on PubMed
- Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial.JAMA Neurol · 2014210 citationsRCR 7.3
- 152 citationsRCR 10.7
- Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.Lancet Oncol · 2019104 citationsRCR 3.3
- Pioglitazone increases the numbers and improves the functional capacity of endothelial progenitor cells in patients with diabetes mellitus.Am Heart J · 200699 citationsRCR 2.4
- IL-1β receptor antagonist reduces inflammation in hemodialysis patients.J Am Soc Nephrol · 201196 citationsRCR 2.7
- Concurrent and predictive validation of a novel robotic surgery simulator: a prospective, randomized study.J Urol · 201293 citationsRCR 4.6
- Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial.Kidney Int · 201989 citationsRCR 4.2
- IL-1 Inhibition and Vascular Function in CKD.J Am Soc Nephrol · 201781 citationsRCR 3.1
- The effects of mindfulness-based stress reduction program on the mental health of family caregivers: a randomized controlled trial.Psychother Psychosom · 201473 citationsRCR 4.0
- Phase I trial of preoperative chemoradiation plus sorafenib for high-risk extremity soft tissue sarcomas with dynamic contrast-enhanced MRI correlates.Clin Cancer Res · 201369 citationsRCR 2.3